Nova Eye Medical (EYE) Discussion, page-2246

We also already have the US sales numbers which certainly exceeded my expectations for how good the company would perform during the LCD period. I was preparing for sales to be largely flat like it was for competitors yet they still recorded quite tremendous growth of 65%. US is the main market at the moment, doubt the market is expecting much for outside the US considering the fact the company has stated it is currently solely focused on the USA, so any growth we get outside of the US is a plus IMO.

Should be good regardless. It's only valued at 2x revenue so this company isn't even being valued remotely close to a quality growth company yet. I reckon it would be fairly hard to disappoint the market...